| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | BLUEPRINT MEDICINES CORP COM | 2,765,080 | 82,123,000 | 15.48% | ||
| 2 | CHEMOCENTRYX INC | 8,064,019 | 48,707,000 | 9.18% | ||
| 3 | CYTOKINETICS INC | 4,997,071 | 45,873,000 | 8.64% | ||
| 4 | ARRAY BIOPHARMA INC COM | 6,461,186 | 43,613,000 | 8.22% | ||
| 5 | CASCADIAN THERAPEUTICS INC | 18,799,368 | 30,831,000 | 5.81% | ||
| 6 | FORWARD PHARMA A/S | 1,387,853 | 29,145,000 | 5.49% | ||
| 7 | COLUCID PHARMACEUTICALS INC COM | 763,300 | 29,120,000 | 5.49% | ||
| 8 | CONCERT PHARMACEUTICALS INC COM | 2,723,210 | 27,532,000 | 5.19% | ||
| 9 | XENON PHARMACEUTICALS INC | 3,108,905 | 25,182,000 | 4.75% | ||
| 10 | ONCOMED PHARMACEUTICALS INC | 1,812,005 | 20,711,000 | 3.90% | ||
| 11 | GLYCOMIMETICS INC | 2,426,282 | 17,348,000 | 3.27% | ||
| 12 | CTI BIOPHARMA CORP | 44,796,940 | 16,767,000 | 3.16% | ||
| 13 | TOBIRA THERAPEUTICS INC | 399,433 | 15,873,000 | 2.99% | ||
| 14 | Nivalis Therapeutics Inc | 1,709,673 | 13,900,000 | 2.62% | ||
| 15 | ArQule Inc | 7,400,128 | 13,246,000 | 2.50% | ||
| 16 | CYTOMX THERAPEUTICS INC COM | 591,813 | 9,280,000 | 1.75% | ||
| 17 | IMMUNE DESIGN CORP COM | 1,200,000 | 9,096,000 | 1.71% | ||
| 18 | GTX INC | 11,512,000 | 9,014,000 | 1.70% | ||
| 19 | INFINITY PHARMACEUTICALS INC COM | 5,149,644 | 8,033,000 | 1.51% | ||
| 20 | Protagonist Therapeutics, Inc. | 375,000 | 7,924,000 | 1.49% | ||
| 21 | Esperion Therapeutics Inc | 493,872 | 6,840,000 | 1.29% | ||
| 22 | ADURO BIOTECH | 501,155 | 6,229,000 | 1.17% | ||
| 23 | Sunesis Pharmaceuticals, Inc. | 730,361 | 3,192,000 | 0.60% | ||
| 24 | OREXIGEN THERAPEUTICS INC | 10,000,000 | 2,650,000 | 0.50% | PRN | |
| 25 | OREXIGEN THERAPEUTICS INC | 734,976 | 2,440,000 | 0.46% | ||
| 26 | PAIN THERAPEUTICS INC | 2,278,552 | 2,278,000 | 0.43% | ||
| 27 | Pieris Pharmaceuticals | 1,016,593 | 1,858,000 | 0.35% | ||
| 28 | Catalyst Biosciences | 865,773 | 1,048,000 | 0.20% | ||
| 29 | GLOBEIMMUNE INC | 657,653 | 822,000 | 0.15% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000921895-16-006168, filed 2016.11.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
